1. The deal, the largest ever in the healthcare sector is sure to draw political ire in a US presidential election year.

2. Pfizer would re-domicile to Ireland where Allergan is registered in a so-called 'inversion' that would slash its corporate tax rate.
3. It will also reignite debate in the pharmaceutical industry over the role of research and development with Allergan Chief Executive Brent Saunders, a prolific deal maker and a skeptic of in-house drug discovery joining the combined company in a position to influence its strategy.
4. The deal would involve Pfizer paying with 11.3 of its shares for each Allergan share. There will also be a small cash component, accounting for less than 10 percent of the value of the deal.
5. Pfizer's Chief Executive Ian Read, 62, will be CEO of the combined company, with Allergan's CEO Brent Saunders, 45, serving in a very senior role focused on operations and the integration.

Latest News  from Business News Desk